Production of therapeutic
proteins in plants
Therapeutic proteins
• Proteins which are engineered in the
laboratory for pharmaceutical use are
referred to as therapeutic proteins .
• Proteins which are absent or low in
individuals with an illness such as Cancer,
Infectious diseases, Hemophilia, Anemia,
Multiple sclerosis, Hepatitis B/C etc. are
artificially synthesized on large scale through
genetically modified host cells and delivered.
Therapeutic proteins
• This therapeutic approach in treating diseases
using proteins and peptides is termed protein
therapeutics.
• Introduced in 1920’s Human insulin is
considered to be the first therapeutic protein
Gene transfer method
Partical bombardment
Plant gene expression strategies
1. Stable nuclear
transformation
2. Plastid
transformation
3. Transient
transformation
Nuclear transformation
Monoclonal Antibodies
Plantibodies
• Plantibodies - monoclonal antibodies
produced in plants
• Plants used include tobacco, corn, potatoes,
soy, alfalfa, and rice
• Examples: cancer, dental caries, herpes
simplex virus, respiratory syncytial virus –
• **GE Corn can produce up to 1 kg
antibody/acre and can be stored at RT for up
to 5 years. Curr Opin Drug Discover Dev 2010
Examples of edible vaccines under
development:
• pig vaccine in corn
• HIV-suppressing protein in spinach
• human vaccine for hepatitis B in potato
Products on the market
Avidin by Sigma
• transgenic corn
• traditionally isolated from chicken egg whites
• used in medical diagnostics
GUS (β-glycuronidase) by Sigma
• transgenic corn
• traditionally isolated from bacterial sources (E.Coli)
• used as visual marker in research labs
Trypsin by Sigma
• transgenic corn
• traditionally isolated from bovine pancreas
• variety of applications, including biopharmaceutical processing
• first large scale transgenic plant product
• Worldwide market = US$280 million in 2014 .
Using plant systems
Advantages
• Cost reduction
- low/no inputs
- low capital cost
• Stability
- storage
• Safety
- eukaroytic production system
- free of animal viruses (e.g. BSE)
Disadvantages
• Environment contamination
- gene flow
- wildlife exposure
• Food supply contamination
- mistaken/intentional mixing w/human food
• Health safety concerns
- Variable, case-specific
Bio-safety issues
Production of therapeutic proteins in plants
Production of therapeutic proteins in plants
Production of therapeutic proteins in plants

Production of therapeutic proteins in plants

  • 1.
  • 2.
    Therapeutic proteins • Proteinswhich are engineered in the laboratory for pharmaceutical use are referred to as therapeutic proteins . • Proteins which are absent or low in individuals with an illness such as Cancer, Infectious diseases, Hemophilia, Anemia, Multiple sclerosis, Hepatitis B/C etc. are artificially synthesized on large scale through genetically modified host cells and delivered.
  • 3.
    Therapeutic proteins • Thistherapeutic approach in treating diseases using proteins and peptides is termed protein therapeutics. • Introduced in 1920’s Human insulin is considered to be the first therapeutic protein
  • 6.
  • 7.
  • 8.
    Plant gene expressionstrategies 1. Stable nuclear transformation 2. Plastid transformation 3. Transient transformation
  • 9.
  • 15.
  • 18.
    Plantibodies • Plantibodies -monoclonal antibodies produced in plants • Plants used include tobacco, corn, potatoes, soy, alfalfa, and rice • Examples: cancer, dental caries, herpes simplex virus, respiratory syncytial virus – • **GE Corn can produce up to 1 kg antibody/acre and can be stored at RT for up to 5 years. Curr Opin Drug Discover Dev 2010
  • 24.
    Examples of ediblevaccines under development: • pig vaccine in corn • HIV-suppressing protein in spinach • human vaccine for hepatitis B in potato
  • 25.
    Products on themarket Avidin by Sigma • transgenic corn • traditionally isolated from chicken egg whites • used in medical diagnostics GUS (β-glycuronidase) by Sigma • transgenic corn • traditionally isolated from bacterial sources (E.Coli) • used as visual marker in research labs Trypsin by Sigma • transgenic corn • traditionally isolated from bovine pancreas • variety of applications, including biopharmaceutical processing • first large scale transgenic plant product • Worldwide market = US$280 million in 2014 .
  • 26.
    Using plant systems Advantages •Cost reduction - low/no inputs - low capital cost • Stability - storage • Safety - eukaroytic production system - free of animal viruses (e.g. BSE)
  • 27.
    Disadvantages • Environment contamination -gene flow - wildlife exposure • Food supply contamination - mistaken/intentional mixing w/human food • Health safety concerns - Variable, case-specific
  • 28.